Patients Enrolled

• Pulnovo Medical has enrolled the first two U.S. patients in its PULSE-LHD clinical trial at Henry Ford Hospital in Detroit. • The trial is conducted under an FDA Investigational Device Exemption (IDE) to evaluate pulmonary artery denervation for treating pulmonary hypertension associated with left heart disease. • This study is significant as it tests a novel medical device approach to managing complex heart failure and pulmonary hypertension conditions.

• The first patients have been enrolled in a record-breaking clinical trial for two potential Ebola drugs in the Ituri region of the Democratic Republic of the Congo. • The research program was launched with unprecedented speed, beginning just six weeks after the WHO declared the outbreak a public health emergency on May 17. • This trial is critical because there are currently no approved drugs available to help medical teams treat patients and reduce mortality rates during the outbreak.

Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will reduce mortality ratesThere is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the first patients are enrolled in a treatment trial.It is a record pace to set up and start this kind of research, scientists said, with patients enrolled just six weeks after the outbreak being declared a public health emergency of international concern by the World Health Organization (WHO) on 17 May. Continue reading...